NCT03506633View on ClinicalTrials.gov

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

January 17, 2022

Study Completion Date

January 17, 2022

Conditions
Peripheral Arterial DiseasePeripheral Artery Disease
Interventions
DIETARY_SUPPLEMENT

MitoQ

"A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each participant in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured."

Trial Locations (1)

68182

University of Nebraska - Omaha, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER

NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients | Biotech Hunter | Biotech Hunter